Feature|Videos|November 26, 2024
KinetiSol® Technology: Disrupting the Solid Amorphous Dispersion Landscape
Author(s)Austin Px
Elizabeth Hickman (Chief Business Officer, AustinPx) explains the company's approach to improving bioavailability, highlighting KinetiSol technology.
Elizabeth Hickman joined Pharmaceutical Technology to provide an overview of AustinPx, the company's bioavailability offerings, and KinetiSol technology, which represents a major breakthrough in amorphous dispersions. Learn more about:
- How AustinPx was created and the strategy behind taking a technology company and turning it into a CDMO;
- The origin of KinetiSol and how it can provide a faster, broader, and greener technology for amorphous solid dispersions;
- How KinetiSol can alleviate challenges associated with spray drying.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
European Parliament Revamps Pharmaceutical Policy Framework
2
Tjoapack’s Advanced Packaging Expansion Aims to Meet Rising Demand
3
Regulatory Expectations for Evaluating GMP Facilities and Equipment
4
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
5
